Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.
|
31504139 |
2019 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The use of immunohistological staining to detect the level of expression of the c-erbB-2 protein in human breast adenocarcinomas may be of value in predicting tumour behaviour.
|
2885574 |
1987 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Trastuzumab® is used for human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.
|
29277796 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
HER-2/neu immunopositivity was more prevalent in adenocarcinomas than in LMP tumors, and the proportion of HER-2/neu-positive adenocarcinomas increased with the progression of the disease.
|
9398993 |
1997 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
None of 40 patients with proximal lesions had overexpression of HER-2/neu, whereas four of 40 (10%) distal adenocarcinomas had a 16-24-fold gene amplification (P = 0.04).
|
7851555 |
1995 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The overexpression of HER2 is among those changes and is often detected in adenocarcinomas such as breast, ovarian, lung, and gastric cancer.
|
10950153 |
2000 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Human epidermal growth factor receptor 2 (HER2) is expressed in some gastric and gastroesophageal junction adenocarcinomas.
|
30624589 |
2019 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
EGFR and HER2 proteins were expressed in 23 and 17 of 55 adenocarcinomas with MX.
|
16189154 |
2005 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Only 2 AVCs (7.7%; both intestinal-type) showed a HER2 overexpression (both 2+), which corresponded to a HER2 gene amplification at CISH analysis.
|
29731265 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.
|
3345525 |
1988 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The median age was 60.1 ± 14.5 (standard deviation) years; 89% (n = 106/119) had performance status 0/1 at diagnosis; 79% (n = 103/130) were non- or former smokers; 93% (n = 120/129) had adenocarcinomas and 74%(n = 97)/19%(n = 25)/7%(n = 10) had disease stages IV/III/I-II at diagnosis, respectively; co-mutations included EGFR (n = 2), BRAF (n = 2), KRAS (n = 1), and HER2 (n = 1).
|
28762087 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma.
|
14607699 |
2002 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This study aimed to investigate the role and relationship of Her2 and HSP90 in gastric and gastro-esophageal adenocarcinomas.
|
23874879 |
2013 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported.
|
29561699 |
2018 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In cervical adenocarcinomas, expression of c-myc was seen in 5 of 7 cases (71.6%), EGFR in all cases and c-erbB-2 in 2 of 7 cases (28.6%). c-myc immunoactivity was observed as nuclear or cytoplasmic stain or both, EGFR as membrane and cytoplasmic stain, c-erbB-2 as membrane stain.
|
1687493 |
1991 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
HER-2 negativity may represent a predictor of pathologic response to neoadjuvant chemotherapy for gastric and oesophago-gastric junction adenocarcinoma.
|
28276033 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Of the 34 cases, three well differentiated adenocarcinomas had extremely high levels of p185ERBB2.
|
1979253 |
1990 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we conducted immunohistochemical analysis and fluorescence in situ hybridization (FISH) for HER2 on 49 primary nonampullar small intestinal adenocarcinomas.
|
21088150 |
2010 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
|
14744769 |
2004 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The postoperative 5-year survival rate of patients with adenocarcinoma according to the expression of HER2 scores 0, 1, 2 and 3 was 75.3%, 77.8%, 76.5% and 20.0%, respectively.
|
22199341 |
2011 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Hepatoid adenocarcinomas showed relatively frequent expressions of HER2 (score 3+/2+: 21%/19%).
|
30946937 |
2019 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression levels of p21(WAF1/CIP1) and HER-2/neu were examined imunohistochemically and the amplification of HER-2/neu gene was evaluated by fluorescence in situ hybridisation in HER-2/neu overexpressing adenocarcinomas.
|
15190415 |
2004 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas.
|
11360194 |
2001 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component.
|
30825613 |
2019 |